The Union Cycliste Internationale (UCI) announced today that it has notified the Russian rider of an Adverse Analytical Finding (AAF) of Meldonium in a sample collected during an out-of-competition control on 14 January 2016.
Melodium is an anti-ischemic drug used to treat patients with chronic heart failure. It was added to the Prohibited List on 1 January 2016, classified as as S.4.5.3 “Hormone and Metabolic Modulators”.
This constitutes the second AAF for a member of the Katusha within a twelve month period, after Italian rider Luca Paolini returned a positive result for cocaine during the Tour de France last year.
Under the current UCI Anti-Doping Rules, this second violation means the Katusha team may receive a 15-45 day suspension from competition. The UCI has referred the matter to the Disciplinary Commission, which will render a decision in the coming days.
Katusha confirmed in a press release that this substance has never been used by the team in any form and was not provided to the rider by the team.
“In accordance with Team Katusha’s zero tolerance policy, Eduard Vorganov has been suspended from all team activities, effective immediately,” said the team.
“In the event that Eduard Vorganov took this product on his own initiative, Team Katusha will conduct an investigation as such conduct is in breach of the Team’s strict medical and anti-doping internal rules.”
The team have confirmed that they are fully committed to fighting doping and are “extremely disappointed that a situation like this could occur despite these measures.”
Vorganov is currently awaiting the results of his B sample.